Literature DB >> 28132131

Evaluation of a novel 5-group classification system of sepsis by vasopressor use and initial serum lactate in the emergency department.

Kai E Swenson1, James D Dziura2, Ani Aydin3, Jesse Reynolds2, Charles R Wira4.   

Abstract

Prognostication in sepsis is limited by disease heterogeneity, and measures to risk-stratify patients in the proximal phases of care lack simplicity and accuracy. Hyperlactatemia and vasopressor dependence are easily identifiable risk factors for poor outcomes. This study compares incidence and hospital outcomes in sepsis based on initial serum lactate level and vasopressor use in the emergency department (ED). In a retrospective analysis of a prospectively identified dual-center ED registry, patients with sepsis were categorized by ED vasopressor use and initial serum lactate level. Vasopressor-dependent patients were categorized as dysoxic shock (lactate >4.0 mmol/L) and vasoplegic shock (≤4.0 mmol/L). Patients not requiring vasopressors were categorized as cryptic shock major (lactate >4.0 mmol/L), cryptic shock minor (>2.0 and ≤4.0 mmol/L), and sepsis without lactate elevation (≤2.0 mmol/L). Of 446 patients included, 4.9% (n = 22) presented in dysoxic shock, 11.7% (n = 52) in vasoplegic shock, 12.1% (n = 54) in cryptic shock major, 30.9% (n = 138) in cryptic shock minor, and 40.4% (n = 180) in sepsis without lactate elevation. Group mortality rates at 28 days were 50.0, 21.1, 18.5, 12.3, and 7.2%, respectively. After adjusting for potential confounders, odds ratios for mortality at 28 days were 15.1 for dysoxic shock, 3.6 for vasoplegic shock, 3.8 for cryptic shock major, and 1.9 for cryptic shock minor, when compared to sepsis without lactate elevation. Lactate elevation is associated with increased mortality in both vasopressor dependent and normotensive infected patients presenting to the emergency department (ED). Cryptic shock mortality (normotension + lactate >4 mmol/L) is equivalent to vasoplegic shock mortality (vasopressor requirement + lactate <4 mmol/L) in our population. The odds of normotensive, infected patients decompensating is three to fourfold higher with hyperlactemia. The proposed Sepsis-3 definitions exclude an entire group of high-risk ED patients. A simple classification in the ED by vasopressor requirement and initial lactate level may identify high-risk subgroups of sepsis. This study may inform prognostication and triage decisions in the proximal phases of care.

Entities:  

Keywords:  Cryptic shock; Lactate; Sepsis; Septic shock; Severe sepsis; Vasopressor

Mesh:

Substances:

Year:  2017        PMID: 28132131     DOI: 10.1007/s11739-017-1607-y

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  34 in total

1.  Critical care in the emergency department: A physiologic assessment and outcome evaluation.

Authors:  H B Nguyen; E P Rivers; S Havstad; B Knoblich; J A Ressler; A M Muzzin; M C Tomlanovich
Journal:  Acad Emerg Med       Date:  2000-12       Impact factor: 3.451

2.  Clinical predictors of adverse outcome in severe sepsis patients with lactate 2-4 mM admitted to the hospital.

Authors:  Y Tang; J Choi; D Kim; L Tudtud-Hans; J Li; A Michel; H Baek; A Hurlow; C Wang; H B Nguyen
Journal:  QJM       Date:  2014-09-04

3.  Mortality in Emergency Department Sepsis (MEDS) score: a prospectively derived and validated clinical prediction rule.

Authors:  Nathan I Shapiro; Richard E Wolfe; Richard B Moore; Eric Smith; Elizabeth Burdick; David W Bates
Journal:  Crit Care Med       Date:  2003-03       Impact factor: 7.598

4.  Systemic inflammatory response syndrome criteria in defining severe sepsis.

Authors:  Kirsi-Maija Kaukonen; Michael Bailey; David Pilcher; D Jamie Cooper; Rinaldo Bellomo
Journal:  N Engl J Med       Date:  2015-03-17       Impact factor: 91.245

5.  Multicenter observational study of the development of progressive organ dysfunction and therapeutic interventions in normotensive sepsis patients in the emergency department.

Authors:  Ryan C Arnold; Robert Sherwin; Nathan I Shapiro; Jennifer L O'Connor; Lindsey Glaspey; Sam Singh; Patrick Medado; Stephen Trzeciak; Alan E Jones
Journal:  Acad Emerg Med       Date:  2013-05       Impact factor: 3.451

6.  Performance of the Mortality in Emergency Department Sepsis score for predicting hospital mortality among patients with severe sepsis and septic shock.

Authors:  Alan E Jones; Kristen Saak; Jeffrey A Kline
Journal:  Am J Emerg Med       Date:  2008-07       Impact factor: 2.469

Review 7.  Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome.

Authors:  J C Marshall; D J Cook; N V Christou; G R Bernard; C L Sprung; W J Sibbald
Journal:  Crit Care Med       Date:  1995-10       Impact factor: 7.598

8.  Occult hypoperfusion and mortality in patients with suspected infection.

Authors:  Michael D Howell; Michael Donnino; Peter Clardy; Daniel Talmor; Nathan I Shapiro
Journal:  Intensive Care Med       Date:  2007-07-06       Impact factor: 17.440

9.  Characteristics and outcomes of patients with vasoplegic versus tissue dysoxic septic shock.

Authors:  Sarah A Sterling; Michael A Puskarich; Nathan I Shapiro; Stephen Trzeciak; Jeffrey A Kline; Richard L Summers; Alan E Jones
Journal:  Shock       Date:  2013-07       Impact factor: 3.454

10.  The shock index as a predictor of vasopressor use in emergency department patients with severe sepsis.

Authors:  Charles R Wira; Melissa W Francis; Sundeep Bhat; Robert Ehrman; David Conner; Mark Siegel
Journal:  West J Emerg Med       Date:  2014-02
View more
  2 in total

1.  The incidence and outcome of severe hyperlactatemia in critically ill patients.

Authors:  Amin Gharipour; Rouzbeh Razavi; Mojgan Gharipour; Reza Modarres; Pouya Nezafati; Nooshin Mirkheshti
Journal:  Intern Emerg Med       Date:  2020-05-15       Impact factor: 3.397

2.  Independent Risk Factors for Sepsis-Associated Cardiac Arrest in Patients with Septic Shock.

Authors:  Won Soek Yang; Youn-Jung Kim; Seung Mok Ryoo; Won Young Kim
Journal:  Int J Environ Res Public Health       Date:  2021-05-07       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.